Skip to main content

GALT

Stock
Health Care
Biotechnology

Performance overview

GALT Price
Price Chart

Forward-looking statistics

Beta
1.14
Risk
95.40%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Company info

SectorHealth Care
IndustryBiotechnology
Employees33
Market cap$161.6M

Fundamentals

Enterprise value$236.8M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity-0.97

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.72
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$3M
Avg trading volume (10 day)$3M
Put-call ratio

Macro factor sensitivity

Growth+4.0
Credit+0.5
Liquidity+1.0
Inflation+0.5
Commodities+0.6
Interest Rates-1.0

Valuation

Dividend yield0.00%
PEG Ratio-1.30
Price to sales
P/E Ratio-1.30
Enterprise Value to Revenue
Price to book-1.23

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday?

On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.

Benzinga (December 20, 2024)
Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks

The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research (December 9, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free